TRIP11 sirna

TRIP11 siRNA (Human)

Cat. Num. AAA829648

• Gene Names: TRIP11; ACG1A; CEV14; GMAP210; TRIP-11; TRIP230; GMAP-210
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: TRIP11; TRIP11 siRNA (Human); CEV14; Thyroid receptor-interacting protein 11; TR-interacting protein 11; TRIP-11; Clonal evolution-related gene on chromosome 14 protein; Golgi-associated microtubule-binding protein 210; GMAP-210; Trip230; TRIP11 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: TRIP11 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 1979

• Applicable Applications for TRIP11 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human TRIP11 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for TRIP11 sirna

siRNA to inhibit TRIP11 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 190194412
• NCBI GeneID: 9321
• NCBI Accession #: NP_004230.2
• NCBI GenBank Nucleotide #: NM_004239.3
• UniProt Accession #: Q15643; O14689; O15154; O95949; B2RUT2
• Molecular Weight: 227,586 Da
• NCBI Official Full Name: thyroid receptor-interacting protein 11
• NCBI Official Synonym Full Names: thyroid hormone receptor interactor 11
• NCBI Official Symbol: TRIP11
• NCBI Official Synonym Symbols: ACG1A; CEV14; GMAP210; TRIP-11; TRIP230; GMAP-210
• NCBI Protein Information: thyroid receptor-interacting protein 11
• UniProt Protein Name: Thyroid receptor-interacting protein 11
• Protein Family: Thyroid receptor-interacting protein
• UniProt Gene Name: TRIP11
• UniProt Synonym Gene Names: CEV14; TR-interacting protein 11; TRIP-11; GMAP-210
• UniProt Entry Name: TRIPB_HUMAN

NCBI Description

This gene was identified based on the interaction of its protein product with thyroid hormone receptor beta. This protein is associated with the Golgi apparatus. The N-terminal region of the protein binds Golgi membranes and the C-terminal region binds the minus ends of microtubules; thus, the protein is thought to play a role in assembly and maintenance of the Golgi ribbon structure around the centrosome. Mutations in this gene cause achondrogenesis type IA.[provided by RefSeq, Mar 2010]

Uniprot Description

TRIP11: Binds the ligand binding domain of the thyroid receptor (THRB) in the presence of triiodothyronine and enhances THRB- modulated transcription. Golgi auto-antigen; probably involved in maintaining cis-Golgi structure. A chromosomal aberration involving TRIP11 may be a cause of acute myelogenous leukemia. Translocation t(5;14)(q33;q32) with PDGFRB. The fusion protein may be involved in clonal evolution of leukemia and eosinophilia. Defects in TRIP11 are the cause of achondrogenesis type 1A (ACG1A). A form of achondrogenesis type 1, a lethal form of chondrodysplasia characterized by deficient ossification in the lumbar vertebrae and absent ossification in the sacral, pubic and ischial bones and clinically by stillbirth or early death. In addition to severe micromelia, there is a disproportionately large cranium due to marked edema of soft tissues.

Protein type: Nuclear receptor co-regulator; Transcription, coactivator/corepressor

Chromosomal Location of Human Ortholog: 14q31-q32

Cellular Component: Golgi membrane; Golgi apparatus; inner acrosomal membrane; cytoskeleton; cis-Golgi network; nucleus

Molecular Function: protein binding; transcription coactivator activity

Biological Process: transcription from RNA polymerase II promoter; organelle organization and biogenesis; protein targeting to Golgi

Disease: Achondrogenesis, Type Ia